CorCMR Study
Microvascular Angina frequently diagnosed as Non-cardiac Chest Pain - Big Implications for overall Chronic Angina Prevalence
In a conversation with Uwe Tigör, Chief Medical Officer of Auxilius Pharma, Prof. Colin Berry, a cardiology and imaging specialist from the University of Glasgow, discusses the results of the CorCMR study, presented at the American Heart Association Scientific Sessions. The study focuses on the diagnosis of patients presenting with chest pain.
Click on the image to watch the full interview
Chronic stable angina
most often occurs on the background of atherosclerotic coronary artery disease
Current angina treatments are either poorly suited or even contraindicated in patients with significant bradycardia or heart block, as many anti-anginal drugs, such as beta-blockers or non-dihydropyridine calcium channel blockers, may exacerbate these conditions.
1. Marinescu et al. JACC Cardiovasc Imaging. 2015;8(2)210-220. 2. Patel MR et al. N Engl J Med. 2010;362:886-95. 3. Bradly C, Berry C. J Nucl Cardiol. 2022;29;1763-75. 4. Taqueti VR, Di Carli MF. J Am Coll Cardiol. 2018;72(21):2625-2641. 5. Chen JW et al. Am J Cardiol. 1997;80;32-38. 6. Zhu H et al. Clin Ther. 2019;41(10)2137-2152. 7. Kaski JC et al. Circulation. 2018;138;1463-1480. 8.Knuuti, J et al. Eur Heart J. 2020;41,:407-477
Chronic stable angina
is a highly prevalent condition taking a heavy toll on millions of people
It is the symptomatic side of coronary artery disease (CAD), typically manifesting as chest pain and shortness of breath
Our solution - AUX-001 - effective angina symptom-controlling agent
with proven hospitalization reduction effect
Auxilius Pharma is actively working on introducing AUX-001 to key markets worldwide as a first-line medication, taken once daily, based on well-established, long-term efficacy and safety results of the active ingredient nicorandil.
